- Featured Product
- KD/KO Validated
TDP-43 (C-terminal) Polyklonaler Antikörper
TDP-43 (C-terminal) Polyklonal Antikörper für WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 12892-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
12892-1-PBS bindet in WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA TDP-43 (C-terminal) und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | Fusionsprotein |
| Vollständiger Name | TAR DNA binding protein |
| Berechnetes Molekulargewicht | 43 kDa |
| Beobachtetes Molekulargewicht | 43-45 kDa, 35 kDa |
| GenBank-Zugangsnummer | BC001487 |
| Gene symbol | TDP-43 |
| Gene ID (NCBI) | 23435 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Transactivation response (TAR), DNA-binding protein of 43 kDa (also known as TARDBP or TDP-43), was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). 12892-1-AP is a rabbit polyclonal antibody raised against the C-terminal amino acids of human TDP-43. This antibody recognizes the cleavage product of 20-30 kDa in addition to the native and phosphorylated forms of TDP-43. Immunohistochemical analyses of TDP-43 using this antibody detect both normal diffuse nuclear staining and insoluble inclusions in pathologic tissues. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phosphoprotein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659,19823856,21666678,22193176)
Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)































